CRISPR Therapeutics

CRSP

Market cap $5.42B

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Time: 9:55 a.m.

Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Roku isn't subject to the same challenges as streaming content creators and providers. ServiceNow is competing with more AI workflow developers than the world plausibly needs, but none of its rivals are toppling the defining (and fast-growing) company.

CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead. The stock could soar if it delivers strong clinical progress over the next 12 months.

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 patients have initiated treatment, supporting a multibillion-dollar opportunity with a large, underpenetrated addressable market. CRSP's pipeline offers near-term catalysts in autoimmune and in-vivo gene editing, with several Phase 1 updates expected later this year.